Osteoporosis: Pathogenesis, New Therapies and Surgical Implications

Clinics in Podiatric Medicine and Surgery

Volumn 24, Issue 2, 2007, Pages 311-332

  Labovitz, Jonathan M ^a,b,c   Revill, Kate ^d  

^a West Los Angeles Veterans Administration Medical Center ^*  (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Baja Project for Crippled Children   (United States)

^d SAMUEL MERRITT COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FLUORIDE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT GROWTH HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; THIAZIDE DIURETIC AGENT; VITAMIN D;

BONE DENSITY; DIET THERAPY; FRACTURE HEALING; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; INCIDENCE; NAUSEA; NONHUMAN; ORTHOPEDIC SURGERY; OSTEOPOROSIS; PATHOGENESIS; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ARTHRITIS; AUTOIMMUNE DISEASES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS; RALOXIFENE; SURGICAL PROCEDURES, OPERATIVE;

EID: 34047257058     PISSN: 08918422     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpm.2006.12.002     Document Type: Review

References (85)

1. Lane N. Epidemiology, etiology and diagnosis of osteoporosis. Am J Obstr Gyn 194 (2006) S3-S11
2. Friedlander A.H., and Jones L.J. The biology, medical management, and podiatric implications of menopause. J Am Podiatr Med Assoc 92 8 (2002) 437-443
3. Gass M., and Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 119 4A (2006) 3S-11S
4. Pogoda P., Priemel M., and Rueger J.M. Bone remodeling: new aspects of a key process that controls skeletal maintenance and repair. Osteoporos Int 16 Suppl 2 (2005) S18-S24
5. Holstead Jones D., Kong Y.Y., and Penninger J.M. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61 (2002) 32-39
6. Das U. Nitiric oxide as the mediator of the anti-osteoporotic actions of estrogen, statins, and essential fatty acids. Exp Biol Med 227 2 (2002) 88-93
7. Hofbauer L.C., Kuhne C.A., and Viereck V. The OPG/RANKL/RANK systems in metabolic bone diseases. J Musculoskel Neuron Interact 4 3 (2004) 268-275
8. Rogers A., Saleh G., Hannon R.A., et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in post-menopausal women. J Clin Endocrinol Metab 87 (2002) 4470-4475
9. Fan X., Roy E., Zhu L., et al. Nitric oxide regulates receptor activity of nuclear factor-kappa B ligand and osteoprotegrin expression in bone marrow stromal cells. Endocrinology 145 2 (2004) 751-759
10. Seck T., Diel I., Bismar H., et al. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegrin and RANKL mRNA in human bone samples. Eur J Endocrinol 145 (2001) 199-205
11. Das UN. Essential fatty acids and osteoporosis. Nutrition 2000;16:386-390.
12. Wimalawansa S.J. Nitorglycerin therapy is as efficacious as standard estrogen therapy (premarin) in prevention of oopherectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res 15 (2000) 2240-2244
13. Van't Hof R., Macphee J., Libouban H., et al. Regulation of bone mass and turnover by neuronal nitric oxide synthase. Endocrinology 145 11 (2004) 5068-5074
14. Levy R., Prince J., and Billiar T. Nitric oxide: a clinical primer. Crit Care Med 33 12 (2005) S492-S495
15. Afzal F., Polak J., and Buttery L. Endothelial nitric oxide synthase in the control of osteoblastic mineralizing activity and bone integrity. J Pathol 202 (2004) 503-510
16. Li F., and Muhlbauer R.C. Food fractionation is a powerful tool to increase bone mass in growing rats and decrease bone loss in aged rats: modulation of the effect by dietary phosphate. J Bone Miner Res 14 (1999) 1457-1465
17. Clowes J.A., Khosla S., and Eastell R. Perspective: potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res 20 9 (2005) 1497-1506
18. Pasco J., Henry M., Sanders K., et al. Beta-androgenic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 19 1 (2004) 19-24
19. Takeda S., Elefteriou F., Levasseur R., et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 111 (2002) 305-317
20. Kinjo M., Setoguchi S., Schneeweiss S., et al. Bone mineral density subjects using central nervous system-active medications. Am J Med 118 12 (2005) 7-12
21. Lang T., LeBlanc A., Evans H., et al. Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J Bone Miner Res 19 (2004) 1006-1012
22. Lin J., and Lane J. Osteoporosis: a review. Clin Orthop Rel Res 425 (2004) 126-134
23. Delaney M. Strategies for the prevention and treatment of osteoporosis during early post-menopause. Am J Obstet Gynecol 194 2 (2006) S12-S23
24. Ishida Y., and Kawai S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi Osteoporosis Prevention Study. Am J Med 117 (2004) 549-555
25. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
26. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction in vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282 (1999) 637-645
27. Powles T.J., Hickish T., Kanis J.A., et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 (1996) 78-84
28. Simoncini T., Mannellea P., Fornari L., et al. Tobulone activates nitric oxide synthesis in human endothelial cells. J Clin Endocrinol Metab 89 9 (2004) 4594-4600
29. Haskell S. Selective estrogen receptor modulators. South Med J 96 5 (2003) 469-476
30. Wilkins C., and Birge S. Prevention of osteoporosis fractures in the elderly. Am J Med 118 (2005) 1190-1195
31. Zizic T. Pharmacological prevention of osteoporotic fractures. Am Fam Physician 70 7 (2004) 1293-1300
32. MacFarlane S., Muniyappa R., Shin J., et al. Osteoporosis and cardiovascular disease. Endocrine 23 1 (2004) 1-10
33. Sama A., Khan S., Myers E., et al. High-dose alendronate uncouples osteoclast and osteoblast function: a study in rat spine pseudoarthritis model. Clin Ortho Rel Res 425 (2004) 135-142
34. Tonino R.P., Meunier P.J., Emkey R., et al. Skeletal benefits of alendronate: 7-year treatment of postemenopausal osteporotic women: Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85 (2000) 3109-3115
35. Emkey R., Reid I., Mulloy A., et al. Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women. J Bone Miner Res (2002) S1059
36. Boniva (ibandronate sodium) [prescribing information] (2005), Roche Laboratories Inc., Nutley, NJ
37. Actonel (risedronate sodium) [prescribing information] (2004), Aventis Pharmaceuticals Inc., Kansas City, MO
38. Rosen C., and Bilezikian J. Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86 3 (2001) 957-964
39. Koester M., and Spindler K. Pharmacologic agents in fracture healing. Clin Sports Med 25 (2006) 63-73
40. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
41. Mundy G., Garrett R., Harris S., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286 (1999) 1946-1949
42. McFarlane S., Muniyappa R., Francisco R., et al. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 87 4 (2002) 1451-1458
43. Meier C., Schlienger R., Kraenzlin M., et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283 24 (2000) 3205-3210
44. VanStaa T.P., Wegman S., deVries F., et al. Use of statins and risk of fractures. JAMA 285 (2001) 1850-1855
45. Rudman D.V., Feller A.G., Nagrog H.S., et al. Effect of human growth hormone in men over age 60. N Engl J Med 323 (1990) 52-54
46. Kurland E.S., Cosman F., McMahon D.J., et al. Therapy of idiopathic osteoporosis in men with parathyroid hormone: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85 (2000) 3069-3076
47. Baecker N., Boese A., Schoenau E., et al. L-arginine, the natural precursor of NO, is not effective for preventing bone loss in postmenopausal women. J Bone Miner Res 20 (2005) 471-479
48. Mei J., Yeung S., and Kung A. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 86 11 (2001) 5217-5221
49. Mundy G. Nutritional modulators of bone remodeling during aging. Am J Clin Nutr 83 Suppl (2006) 427S-430S
50. Bhandari M., and Devereaux P.J. Do beta blockers and thiazides reduce fracture risk?. Can Med Assoc J 172 1 (2005) 37
51. Rubin C., Recker R., Callen D., et al. Prevention of postmenopausal bone loss by a low magnitude, high frequency mechanical stimuli: a clinical trial assessing compliance, efficacy, and safety. J Bone Miner Res 19 3 (2004) 343-351
52. Rubin J., Murphy T.C., Zhu L., et al. Mechanical strain differentially regulates endothelial nitric-oxide synthase and receptor activator of nuclear kappa B ligand expression via ERK 1/2 MAPK. J Biol Chem 278 (2003) 34018-34025
53. Rubin J., Murphy T., Fan X., et al. Mechanical strain inhibits RANKL expression through activation of ERK 1/2 in bone marrow stromal cells. J Bone Miner Res 17 (2002) 1452-1460
54. Ward K., Alsop C., Caulton J., et al. Low magnitude mechanical loading is osteogenic in children with disabling conditions. J Bone Miner Res 19 (2004) 360-369
55. Judex S., Garman R., Squire M., et al. Genetically based influences on the site-specific regulation of tranecular and cortical bone morphology. J Bone Miner Res 19 (2004) 600-606
56. Xie L. Bone, in press.
57. Hauselmann H.J., and Rizzoli R. A comprehensive review of treatments for post-menopusal osteoporosis. Osteoporos Int 14 (2003) 2-12
58. Hannan M.T., Cheng D.M., Green E., et al. Establishing the compliance in elderly women for use of a low level mechanical stress device in a clinical osteoporosis study. Osteoporos Int 15 (2004) 918-926
59. Holmes G.B., and Hill N. Fractures and dislocations of the foot and ankle in diabetics associated with Charcot joint changes. Foot Ankle Int 4 (1994) 182-185
60. Schon L.C., and Marks R.M. The management of neuropathic fracture dislocation in the diabetic patient. Orthop Clin North Am 26 (1995) 375-392
61. Cornell C.N. Internal fracture fixation in patients with osteoporosis. J Am Acad Orthop Surg 11 (2003) 109-119
62. Egermann M., Schneider E., Evans C.H., et al. The potential for gene therapy for fracture healing in osteoporosis. Osteoporos Int 16 (2005) S120-S128
63. Seebeck J., Goldham J., Morlock M.M., et al. Mechanical behavior of screws in normal and osteoporotic bone. Osteoporos Int 16 (2005) S107-S111
64. Pfiefer B.A., Krag M.H., and Johnson C. Repair of failed transpedicle screw fixation. Spine 19 (1994) 350-353
65. Taniwaki Y., Takemasa R., Tani T., et al. Enhancement of pedicle screw stability using calcium phosphate cement in osteoporotic vertebrae: in vivo biomechanical study. J Orthop Sci 8 (2003) 408-414
66. Moroni A., Faldini C., Pegreffi F., et al. HA-coated screws decrease the incidence of fixation failure in osteoporotic trochanteric fractures. Clin Orthop Rel Res 425 (2004) 87-92
67. Moroni A., Faldini C., Rocca M., et al. Improvement of the bone-screw interface with hydroxyapetite coated AO/ASIF cortical screws. J Orthop Trauma 16 (2002) 257-263
68. Yamamoto H., Niwa S., Hori M., et al. Mechanical strength on calcium phosphate cement in vivo and in vitro. Biomaterials 19 (1998) 1587-1591
69. Iai H., Yamamoto H., Kamioka Y., et al. An experimental study on the biomechanical effect of TCP cement for the vertebra with osteoporosis. Orthop Ceramic Implants 11 (1991) 43-46
70. Schon L.C., Easley M.E., and Weinfeld S.B. Charcot neuroarthropathy of the foot and ankle. Clin Orthop 349 (1998) 116-131
71. Koval K.J., Petraco D.M., Kumer F.J., et al. A new technique for complex fibula fracture fixation in the elderly: a clinical and biomechanical evaluation. J Orthop Trauma 11 (1997) 28-33
72. Kettunen J., and Kroger H. Surgical treatment of ankle and foot fractures in the elderly. Osteoporos Int 16 Suppl 2 (2005) S103-S106
73. Ring D., Kloen P., Kadzielski J., et al. Locking compression plates for osteoporotic nonunions of the diaphyseal humerus. Clin Orthop Rel Res 425 (2004) 50-54
74. Chao E.Y.S., Inoue N., Koo T.K.K., et al. Biomechanical considerations of fracture treatment and bone quality maintenance in elderly patient and patients with osteoporosis. Clin Orthop Res Res 425 (2004) 12-25
75. Bodamyali T., Kanczler S.M., Simon B., et al. PEMF simultaneously induce osteogenesis and upregulate transcription BMP-2 and BMP-4 in rat osteoblasts in vitro. Biochem Biophys Res Commun 250 (1998) 458-461
76. Brighton C.T., and Hunt R.M. Ultrastructure of electrical induced osteogenesis in the rabbit medullary canal. J Orthop Res 4 (1986) 27-36
77. Heckman J.D., Ryaby J.P., McCabe J., et al. Acceleration of tibial fracture-healing by non-invasive low-intensity pulsed ultrasound. J Bone Joint Surg 76-A (1994) 26-34
78. Kristiansen T.K., Ryaby J.P., McCabe J., et al. Accelerated healing of distal radial fractures with the use of specific, low-intensity ultrasound. A multi-center, prospective, randomized, double-blind, placebo-controlled study. J Bone Joint Surg 79-A (1997) 961-973
79. Simpson A.H.R.W., Mills L., and Noble B. The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br 88-B 6 (2006) 701-705
80. Hilding M., Ryd L., Toksvig-Larsen S., et al. Clodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients. Acta Orthop Scand 71 (2000) 553-557
81. Von Knoch F., Cho M.R., Garrigues G.E., et al. Effects of bisphosphonates (alendronate and zoledronate) on bone ingrowth in a rabbit model: a radiographic and histomorphometric analysis. Trans Orthop Res Soc 27 (2003) 1375
82. Shanbhag A.S., Hasselman C.T., and Rubash H.E. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop Rel Res 344 (1997) 33-43
83. Simon A.M., Manigrasso M.B., and O'Connor J.P. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17 (2002) 963-976
84. Reuben S.S., and Ekman E.F. The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. J Bone Joint Surg Am 87 (2005) 536-542
85. Ro J., Sudmann E., and Marton P.F. Effect of indomethacin on fracture healing in rats. Acta Orthop Scand 47 (1976) 588-599